Osteoarthritis Pain Drugs-EMEA Market Status and Trend Report 2013-2023
Report Summary
Osteoarthritis Pain Drugs-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Osteoarthritis Pain Drugs industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole EMEA and Regional Market Size of Osteoarthritis Pain Drugs 2013-2017, and development forecast 2018-2023
Main market players of Osteoarthritis Pain Drugs in EMEA, with company and product introduction, position in the Osteoarthritis Pain Drugs market
Market status and development trend of Osteoarthritis Pain Drugs by types and applications
Cost and profit status of Osteoarthritis Pain Drugs, and marketing status
Market growth drivers and challenges
The report segments the EMEA Osteoarthritis Pain Drugs market as:
EMEA Osteoarthritis Pain Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023)
Europe
Middle East
Africa
EMEA Osteoarthritis Pain Drugs Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Oral
Injection
External
EMEA Osteoarthritis Pain Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Hospitals
Clinics
Other
EMEA Osteoarthritis Pain Drugs Market: Players Segment Analysis (Company and Product introduction, Osteoarthritis Pain Drugs Sales Volume, Revenue, Price and Gross Margin):
Abbott Laboratories
Johnson & Johnson
Novartis International
Pfizer
Abiogen Pharma
Afferent Pharmaceuticals
Astellas Pharma
BioDelivery Sciences International
Crystal Genomics
Cytori Therapeutics
Daiichi Sankyo
Eli Lilly
Endo Pharmaceuticals Holdings
Horizon Pharma
ICeutica
Iroko Pharmaceuticals
Merck
Nuvo Research
Regeneron Pharmaceuticals
Sanofi
SantoSolve
Techfields Pharma
Winston Pharmaceuticals
Yooyoung Pharmaceutical
Zynerba Pharmaceuticals
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Osteoarthritis Pain Drugs-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Osteoarthritis Pain Drugs industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole EMEA and Regional Market Size of Osteoarthritis Pain Drugs 2013-2017, and development forecast 2018-2023
Main market players of Osteoarthritis Pain Drugs in EMEA, with company and product introduction, position in the Osteoarthritis Pain Drugs market
Market status and development trend of Osteoarthritis Pain Drugs by types and applications
Cost and profit status of Osteoarthritis Pain Drugs, and marketing status
Market growth drivers and challenges
The report segments the EMEA Osteoarthritis Pain Drugs market as:
EMEA Osteoarthritis Pain Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023)
Europe
Middle East
Africa
EMEA Osteoarthritis Pain Drugs Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Oral
Injection
External
EMEA Osteoarthritis Pain Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Hospitals
Clinics
Other
EMEA Osteoarthritis Pain Drugs Market: Players Segment Analysis (Company and Product introduction, Osteoarthritis Pain Drugs Sales Volume, Revenue, Price and Gross Margin):
Abbott Laboratories
Johnson & Johnson
Novartis International
Pfizer
Abiogen Pharma
Afferent Pharmaceuticals
Astellas Pharma
BioDelivery Sciences International
Crystal Genomics
Cytori Therapeutics
Daiichi Sankyo
Eli Lilly
Endo Pharmaceuticals Holdings
Horizon Pharma
ICeutica
Iroko Pharmaceuticals
Merck
Nuvo Research
Regeneron Pharmaceuticals
Sanofi
SantoSolve
Techfields Pharma
Winston Pharmaceuticals
Yooyoung Pharmaceutical
Zynerba Pharmaceuticals
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF OSTEOARTHRITIS PAIN DRUGS
1.1 Definition of Osteoarthritis Pain Drugs in This Report
1.2 Commercial Types of Osteoarthritis Pain Drugs
1.2.1 Oral
1.2.2 Injection
1.2.3 External
1.3 Downstream Application of Osteoarthritis Pain Drugs
1.3.1 Hospitals
1.3.2 Clinics
1.3.3 Other
1.4 Development History of Osteoarthritis Pain Drugs
1.5 Market Status and Trend of Osteoarthritis Pain Drugs 2013-2023
1.5.1 EMEA Osteoarthritis Pain Drugs Market Status and Trend 2013-2023
1.5.2 Regional Osteoarthritis Pain Drugs Market Status and Trend 2013-2023
CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Osteoarthritis Pain Drugs in EMEA 2013-2017
2.2 Consumption Market of Osteoarthritis Pain Drugs in EMEA by Regions
2.2.1 Consumption Volume of Osteoarthritis Pain Drugs in EMEA by Regions
2.2.2 Revenue of Osteoarthritis Pain Drugs in EMEA by Regions
2.3 Market Analysis of Osteoarthritis Pain Drugs in EMEA by Regions
2.3.1 Market Analysis of Osteoarthritis Pain Drugs in Europe 2013-2017
2.3.2 Market Analysis of Osteoarthritis Pain Drugs in Middle East 2013-2017
2.3.3 Market Analysis of Osteoarthritis Pain Drugs in Africa 2013-2017
2.4 Market Development Forecast of Osteoarthritis Pain Drugs in EMEA 2018-2023
2.4.1 Market Development Forecast of Osteoarthritis Pain Drugs in EMEA 2018-2023
2.4.2 Market Development Forecast of Osteoarthritis Pain Drugs by Regions 2018-2023
CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES
3.1 Whole EMEA Market Status by Types
3.1.1 Consumption Volume of Osteoarthritis Pain Drugs in EMEA by Types
3.1.2 Revenue of Osteoarthritis Pain Drugs in EMEA by Types
3.2 EMEA Market Status by Types in Major Countries
3.2.1 Market Status by Types in Europe
3.2.2 Market Status by Types in Middle East
3.2.3 Market Status by Types in Africa
3.3 Market Forecast of Osteoarthritis Pain Drugs in EMEA by Types
CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Osteoarthritis Pain Drugs in EMEA by Downstream Industry
4.2 Demand Volume of Osteoarthritis Pain Drugs by Downstream Industry in Major Countries
4.2.1 Demand Volume of Osteoarthritis Pain Drugs by Downstream Industry in Europe
4.2.2 Demand Volume of Osteoarthritis Pain Drugs by Downstream Industry in Middle East
4.2.3 Demand Volume of Osteoarthritis Pain Drugs by Downstream Industry in Africa
4.3 Market Forecast of Osteoarthritis Pain Drugs in EMEA by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF OSTEOARTHRITIS PAIN DRUGS
5.1 EMEA Economy Situation and Trend Overview
5.2 Osteoarthritis Pain Drugs Downstream Industry Situation and Trend Overview
CHAPTER 6 OSTEOARTHRITIS PAIN DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA
6.1 Sales Volume of Osteoarthritis Pain Drugs in EMEA by Major Players
6.2 Revenue of Osteoarthritis Pain Drugs in EMEA by Major Players
6.3 Basic Information of Osteoarthritis Pain Drugs by Major Players
6.3.1 Headquarters Location and Established Time of Osteoarthritis Pain Drugs Major Players
6.3.2 Employees and Revenue Level of Osteoarthritis Pain Drugs Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 OSTEOARTHRITIS PAIN DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Abbott Laboratories
7.1.1 Company profile
7.1.2 Representative Osteoarthritis Pain Drugs Product
7.1.3 Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin of Abbott Laboratories
7.2 Johnson & Johnson
7.2.1 Company profile
7.2.2 Representative Osteoarthritis Pain Drugs Product
7.2.3 Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin of Johnson & Johnson
7.3 Novartis International
7.3.1 Company profile
7.3.2 Representative Osteoarthritis Pain Drugs Product
7.3.3 Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin of Novartis International
7.4 Pfizer
7.4.1 Company profile
7.4.2 Representative Osteoarthritis Pain Drugs Product
7.4.3 Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin of Pfizer
7.5 Abiogen Pharma
7.5.1 Company profile
7.5.2 Representative Osteoarthritis Pain Drugs Product
7.5.3 Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin of Abiogen Pharma
7.6 Afferent Pharmaceuticals
7.6.1 Company profile
7.6.2 Representative Osteoarthritis Pain Drugs Product
7.6.3 Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin of Afferent Pharmaceuticals
7.7 Astellas Pharma
7.7.1 Company profile
7.7.2 Representative Osteoarthritis Pain Drugs Product
7.7.3 Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin of Astellas Pharma
7.8 BioDelivery Sciences International
7.8.1 Company profile
7.8.2 Representative Osteoarthritis Pain Drugs Product
7.8.3 Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin of BioDelivery Sciences International
7.9 Crystal Genomics
7.9.1 Company profile
7.9.2 Representative Osteoarthritis Pain Drugs Product
7.9.3 Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin of Crystal Genomics
7.10 Cytori Therapeutics
7.10.1 Company profile
7.10.2 Representative Osteoarthritis Pain Drugs Product
7.10.3 Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin of Cytori Therapeutics
7.11 Daiichi Sankyo
7.11.1 Company profile
7.11.2 Representative Osteoarthritis Pain Drugs Product
7.11.3 Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin of Daiichi Sankyo
7.12 Eli Lilly
7.12.1 Company profile
7.12.2 Representative Osteoarthritis Pain Drugs Product
7.12.3 Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin of Eli Lilly
7.13 Endo Pharmaceuticals Holdings
7.13.1 Company profile
7.13.2 Representative Osteoarthritis Pain Drugs Product
7.13.3 Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin of Endo Pharmaceuticals Holdings
7.14 Horizon Pharma
7.14.1 Company profile
7.14.2 Representative Osteoarthritis Pain Drugs Product
7.14.3 Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin of Horizon Pharma
7.15 ICeutica
7.15.1 Company profile
7.15.2 Representative Osteoarthritis Pain Drugs Product
7.15.3 Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin of ICeutica
7.16 Iroko Pharmaceuticals
7.17 Merck
7.18 Nuvo Research
7.19 Regeneron Pharmaceuticals
7.20 Sanofi
7.21 SantoSolve
7.22 Techfields Pharma
7.23 Winston Pharmaceuticals
7.24 Yooyoung Pharmaceutical
7.25 Zynerba Pharmaceuticals
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF OSTEOARTHRITIS PAIN DRUGS
8.1 Industry Chain of Osteoarthritis Pain Drugs
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF OSTEOARTHRITIS PAIN DRUGS
9.1 Cost Structure Analysis of Osteoarthritis Pain Drugs
9.2 Raw Materials Cost Analysis of Osteoarthritis Pain Drugs
9.3 Labor Cost Analysis of Osteoarthritis Pain Drugs
9.4 Manufacturing Expenses Analysis of Osteoarthritis Pain Drugs
CHAPTER 10 MARKETING STATUS ANALYSIS OF OSTEOARTHRITIS PAIN DRUGS
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
1.1 Definition of Osteoarthritis Pain Drugs in This Report
1.2 Commercial Types of Osteoarthritis Pain Drugs
1.2.1 Oral
1.2.2 Injection
1.2.3 External
1.3 Downstream Application of Osteoarthritis Pain Drugs
1.3.1 Hospitals
1.3.2 Clinics
1.3.3 Other
1.4 Development History of Osteoarthritis Pain Drugs
1.5 Market Status and Trend of Osteoarthritis Pain Drugs 2013-2023
1.5.1 EMEA Osteoarthritis Pain Drugs Market Status and Trend 2013-2023
1.5.2 Regional Osteoarthritis Pain Drugs Market Status and Trend 2013-2023
CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Osteoarthritis Pain Drugs in EMEA 2013-2017
2.2 Consumption Market of Osteoarthritis Pain Drugs in EMEA by Regions
2.2.1 Consumption Volume of Osteoarthritis Pain Drugs in EMEA by Regions
2.2.2 Revenue of Osteoarthritis Pain Drugs in EMEA by Regions
2.3 Market Analysis of Osteoarthritis Pain Drugs in EMEA by Regions
2.3.1 Market Analysis of Osteoarthritis Pain Drugs in Europe 2013-2017
2.3.2 Market Analysis of Osteoarthritis Pain Drugs in Middle East 2013-2017
2.3.3 Market Analysis of Osteoarthritis Pain Drugs in Africa 2013-2017
2.4 Market Development Forecast of Osteoarthritis Pain Drugs in EMEA 2018-2023
2.4.1 Market Development Forecast of Osteoarthritis Pain Drugs in EMEA 2018-2023
2.4.2 Market Development Forecast of Osteoarthritis Pain Drugs by Regions 2018-2023
CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES
3.1 Whole EMEA Market Status by Types
3.1.1 Consumption Volume of Osteoarthritis Pain Drugs in EMEA by Types
3.1.2 Revenue of Osteoarthritis Pain Drugs in EMEA by Types
3.2 EMEA Market Status by Types in Major Countries
3.2.1 Market Status by Types in Europe
3.2.2 Market Status by Types in Middle East
3.2.3 Market Status by Types in Africa
3.3 Market Forecast of Osteoarthritis Pain Drugs in EMEA by Types
CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Osteoarthritis Pain Drugs in EMEA by Downstream Industry
4.2 Demand Volume of Osteoarthritis Pain Drugs by Downstream Industry in Major Countries
4.2.1 Demand Volume of Osteoarthritis Pain Drugs by Downstream Industry in Europe
4.2.2 Demand Volume of Osteoarthritis Pain Drugs by Downstream Industry in Middle East
4.2.3 Demand Volume of Osteoarthritis Pain Drugs by Downstream Industry in Africa
4.3 Market Forecast of Osteoarthritis Pain Drugs in EMEA by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF OSTEOARTHRITIS PAIN DRUGS
5.1 EMEA Economy Situation and Trend Overview
5.2 Osteoarthritis Pain Drugs Downstream Industry Situation and Trend Overview
CHAPTER 6 OSTEOARTHRITIS PAIN DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA
6.1 Sales Volume of Osteoarthritis Pain Drugs in EMEA by Major Players
6.2 Revenue of Osteoarthritis Pain Drugs in EMEA by Major Players
6.3 Basic Information of Osteoarthritis Pain Drugs by Major Players
6.3.1 Headquarters Location and Established Time of Osteoarthritis Pain Drugs Major Players
6.3.2 Employees and Revenue Level of Osteoarthritis Pain Drugs Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 OSTEOARTHRITIS PAIN DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Abbott Laboratories
7.1.1 Company profile
7.1.2 Representative Osteoarthritis Pain Drugs Product
7.1.3 Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin of Abbott Laboratories
7.2 Johnson & Johnson
7.2.1 Company profile
7.2.2 Representative Osteoarthritis Pain Drugs Product
7.2.3 Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin of Johnson & Johnson
7.3 Novartis International
7.3.1 Company profile
7.3.2 Representative Osteoarthritis Pain Drugs Product
7.3.3 Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin of Novartis International
7.4 Pfizer
7.4.1 Company profile
7.4.2 Representative Osteoarthritis Pain Drugs Product
7.4.3 Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin of Pfizer
7.5 Abiogen Pharma
7.5.1 Company profile
7.5.2 Representative Osteoarthritis Pain Drugs Product
7.5.3 Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin of Abiogen Pharma
7.6 Afferent Pharmaceuticals
7.6.1 Company profile
7.6.2 Representative Osteoarthritis Pain Drugs Product
7.6.3 Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin of Afferent Pharmaceuticals
7.7 Astellas Pharma
7.7.1 Company profile
7.7.2 Representative Osteoarthritis Pain Drugs Product
7.7.3 Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin of Astellas Pharma
7.8 BioDelivery Sciences International
7.8.1 Company profile
7.8.2 Representative Osteoarthritis Pain Drugs Product
7.8.3 Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin of BioDelivery Sciences International
7.9 Crystal Genomics
7.9.1 Company profile
7.9.2 Representative Osteoarthritis Pain Drugs Product
7.9.3 Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin of Crystal Genomics
7.10 Cytori Therapeutics
7.10.1 Company profile
7.10.2 Representative Osteoarthritis Pain Drugs Product
7.10.3 Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin of Cytori Therapeutics
7.11 Daiichi Sankyo
7.11.1 Company profile
7.11.2 Representative Osteoarthritis Pain Drugs Product
7.11.3 Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin of Daiichi Sankyo
7.12 Eli Lilly
7.12.1 Company profile
7.12.2 Representative Osteoarthritis Pain Drugs Product
7.12.3 Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin of Eli Lilly
7.13 Endo Pharmaceuticals Holdings
7.13.1 Company profile
7.13.2 Representative Osteoarthritis Pain Drugs Product
7.13.3 Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin of Endo Pharmaceuticals Holdings
7.14 Horizon Pharma
7.14.1 Company profile
7.14.2 Representative Osteoarthritis Pain Drugs Product
7.14.3 Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin of Horizon Pharma
7.15 ICeutica
7.15.1 Company profile
7.15.2 Representative Osteoarthritis Pain Drugs Product
7.15.3 Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin of ICeutica
7.16 Iroko Pharmaceuticals
7.17 Merck
7.18 Nuvo Research
7.19 Regeneron Pharmaceuticals
7.20 Sanofi
7.21 SantoSolve
7.22 Techfields Pharma
7.23 Winston Pharmaceuticals
7.24 Yooyoung Pharmaceutical
7.25 Zynerba Pharmaceuticals
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF OSTEOARTHRITIS PAIN DRUGS
8.1 Industry Chain of Osteoarthritis Pain Drugs
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF OSTEOARTHRITIS PAIN DRUGS
9.1 Cost Structure Analysis of Osteoarthritis Pain Drugs
9.2 Raw Materials Cost Analysis of Osteoarthritis Pain Drugs
9.3 Labor Cost Analysis of Osteoarthritis Pain Drugs
9.4 Manufacturing Expenses Analysis of Osteoarthritis Pain Drugs
CHAPTER 10 MARKETING STATUS ANALYSIS OF OSTEOARTHRITIS PAIN DRUGS
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
